Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to explore wither ivacaftor in refractory CRS patients
will demonstrate safety and tolerability; restore CFTR-mediated Cl- secretions as measured by
EDSPD testing; produce detectable improvements in validated measures of CRS including the
SNOT-22 questionnaire, Lund-MacKay CT scan grading, and Lund-Kennedy endoscopic scores; and
provide beneficial effects on readily measured markers of sinonasal inflammation and
infection (IP-10, IL-8, and Pseudomonas CFUs).